One_CD
day_NN
..._:
Every_QUAN
day_NN
more_EMPH
than_PIN
27,000_CD
people_NN
are_VPRT [PASS]
diagnosed_VBN
with_PIN
cancer_NN
..._:
over_IN
2,600_CD
people_NN
in_PIN
the_DT
USA_NN
die_VB
from_PIN
heart_NN
disease_NN
..._:
about_IN
100,000_CD
young_JJ
people_NN
become_VPRT
addicted_VBN
to_PIN
tobacco_NN
more_EMPH
than_PIN
3,000_CD
children_NN
in_PIN
Africa_NN
die_NN
of_PIN
malaria_NN
globally_RB
,_,
more_EMPH
than_PIN
8,000_CD
people_NN
die_VPRT
from_PIN
AIDS_NN
._.
Products_NN
for_PIN
the_DT
future_NN
in_PIN
key_JJ
disease_NN
areas_NN
One_CD
day_NN
statistics_NN
such_JJ
as_IN
Diabetes_NN
A_NN
new_JJ
concept_NN
featuring_VBG [WZPRES]
a_DT
PPAR_NN
pan_VB
agonist_NN
._.
677954_CD
,_,
an_DT
Avandia_NN
followthese_NN
will_PRMD
not_XX0
be_VB
as_IN
bleak_JJ
._.
Tona_NN
Gilmer_NN
is_VPRT [BEMA]
on_PIN
a_DT
path_NN
to_PIN
a_DT
up_RB
,_,
promises_VPRT [PUBV]
glucose_NN
and_CC
lipid_JJ
day_NN
she_TPP3
hopes_VPRT [PRIV]
will_PRMD
see_VB [PRIV]
more_EMPH
cures_NN
for_PIN
control_NN
without_PIN
weight_NN
gain_NN
cancer_NN
._.
For_PIN
15_CD
years_NN
,_,
Tona_NN
has_VPRT [PEAS]
been_VBN
and_CC
fluid_JJ
retention_NOMZ
._.
GSK_NN
is_VPRT
playing_VBG
a_DT
leading_VBG
working_GER
in_PIN
oncology_JJ
research_NN
,_,
seeking_VBG
Malaria_NN
In_PIN
2003_CD
we_FPP1
launched_VBD
better_JJ
ways_NN
to_TO
treat_VB
cancer_NN
with_PIN
a_DT
passion_NN
a_DT
new_JJ
anti-malarial_JJ
,_,
Lapdap_NN
,_,
and_ANDC
commitment_NOMZ
borne_VBN [WZPAST]
from_PIN
knowing_VBG [PRIV]
and_CC
we_FPP1
now_TIME
have_VPRT
two_CD
early_TIME
that_DEMO
so_RB
many_QUAN
people_NN
are_VPRT
or_CC
have_VPRT [PEAS]
been_VBN
malaria_NN
compounds_NN
in_PIN
part_NN
in_PIN
tackling_VBG
these_DEMO
global_JJ
affected_VBN
by_PIN
the_DT
disease_NN
._.
We_FPP1
are_VPRT [SPAU]
also_RB
developing_VBG
vaccines_NN
against_PIN
My_FPP1
mother_NN
was_VBD [BEMA]
extremely_AMP
ill_PRED
when_RB
I_FPP1
diseases_NN
of_PIN
the_DT
developing_VBG
was_VBD [BEMA]
a_DT
baby_NN
and_CC
,_,
as_IN
I_FPP1
grew_VBD
up_RB
,_,
I_FPP1
wanted_VBD
challenges_NN
,_,
constantly_RB
world_NN
._.
One_CD
example_NN
is_VPRT [BEMA]
so_RB
much_QUAN
to_TO
know_VB [PRIV]
what_WP [WHCL]
causes_VPRT
illness_NOMZ
Mosquirix_NN
,_,
which_WDT [SERE]
has_VPRT
and_ANDC
why_RB
there_EX
are_VPRT
so_RB
few_QUAN
effective_JJ
demonstrated_VBN [PRIV]
clinical_JJ
proof_NN
treatments_NOMZ
._.
Today_TIME
,_,
as_IN
director_NN
of_PIN
of_PIN
concept_NN
in_PIN
a_DT
field_NN
efficacy_NN
striving_VBG [WZPRES]
to_TO
make_VB
the_DT
world_NN
Oncology_NN
Biology_NN
at_PIN
Research_NN
Triangle_NN
trial_NN
in_PIN
Africa_NN
._.
Park_NN
in_PIN
the_DT
USA_NN
,_,
Tona_NN
and_CC
her_TPP3
team_NN
of_PIN
Heart_NN
disease_NN
GSK_NN
has_VPRT
about_RB
30_CD
scientists_NN
are_VPRT
playing_VBG
a_DT
key_JJ
role_NN
a_DT
number_NN
of_PIN
projects_NN
in_PIN
a_DT
healthier_RB
place_NN
._.
in_PIN
GSKs_NN
efforts_NN
to_TO
find_VB [PRIV]
these_DEMO
treatments_NOMZ
._.
cardiovascular_JJ
research_NN
that_TSUB
hold_VPRT [PRIV]
the_DT
prospect_NN
of_PIN
I_FPP1
have_VPRT [SPAU] [PEAS]
never_RB
lost_VBN
sight_NN
of_PIN
the_DT
bigger_JJ
significantly_RB
improving_VBG
picture_NN
-_:
the_DT
patients_NN
-_:
in_PIN
the_DT
detail_NN
of_PIN
my_FPP1
treatment_NOMZ
options_NOMZ
._.
A_DT
novel_NN
We_FPP1
are_VPRT [SPAU]
now_TIME
beginning_VBG
to_TO
see_VB [PRIV]
implicated_VBN
in_PIN
breast_NN
cancer_NN
and_PHC
GSKs_NN
bold_JJ
and_PHC
creative_JJ
new_JJ
R&D_NN
work_NN
because_CAUS
its_PIT
very_AMP
personal_JJ
._.
class_NN
of_PIN
compounds_NN
targets_VPRT
the_DT
benefits_NN
of_PIN
our_FPP1
innovative_JJ
other_JJ
solid_JJ
tumors_NN
and_CC
may_POMD
help_VB
model_NN
is_VPRT
working_VBG
and_CC
the_DT
company_NN
While_OSUB
much_QUAN
progress_NN
has_VPRT [PEAS]
been_VBN [PASS]
made_VBN
,_,
a_DT
newly_RB
identified_VBN
risk_NN
factor_NN
restructuring_GER
of_PIN
the_DT
R&D_NN
process_NN
convert_VPRT
the_DT
management_NOMZ
of_PIN
some_QUAN
is_VPRT
developing_VBG
more_EMPH
quality_NOMZ
for_PIN
heart_NN
disease_NN
,_,
an_DT
enzyme_NN
the_DT
end_NN
of_PIN
Tonas_NN
path_NN
remains_VPRT
unclear_JJ
._.
As_CONJ
a_NULL
result_NULL
cancers_NN
to_PIN
chronic_JJ
stable_JJ
disease_NN
compounds_NN
than_PIN
ever_RB
before_RB
._.
These_DEMO
Perhaps_RB
as_IN
we_FPP1
search_VPRT
for_PIN
clues_NN
to_PIN
a_DT
cure_NN
,_,
of_PIN
dramatically_RB
improved_VBN
rates_NN
of_PIN
states_NN
._.
inhibitors_NN
sharply_RB
lower_JJ
the_DT
productivity_NOMZ
,_,
the_DT
whole_JJ
span_NN
of_PIN
our_FPP1
That_DEMP
has_VPRT
to_TO
be_VB [BEMA]
good_JJ
news_NN
for_PIN
we_FPP1
can_POMD
treat_VB
cancer_NN
in_PIN
a_DT
way_NN
that_DEMO
activity_NOMZ
of_PIN
this_DEMO
enzyme_NN
in_PIN
pipeline_NN
is_VPRT [BEMA]
strong_PRED
and_CC
bursting_VBG
with_PIN
In_PIN
phase_NN
I_FPP1
studies_NN
among_PIN
patients_NN
patients_NN
around_PLACE
the_DT
world_NN
waiting_VBG [WZPRES]
becomes_VPRT
more_EMPH
like_IN
treating_VBG
chronic_JJ
atherosclerotic_JJ
plaque_NN
,_,
which_WDT [SERE]
potential_NN
._.
Where_RB
once_TIME
a_DT
disease_NN
who_WP [WHSUB]
had_VBD [PEAS]
failed_VBN
multiple_JJ
prior_RB
for_PIN
new_JJ
and_CC
better_RB
treatments_NOMZ
in_PIN
diseases_NN
._.
GSKs_NN
compound_VPRT
in_PIN
is_VPRT [PASS]
expected_VBN [PRIV]
to_TO
reduce_VB
was_VBD [PASS]
thought_VBN [PRIV]
to_TO
be_VB [BEMA]
untreatable_PRED
,_,
treatments_NOMZ
with_PIN
other_JJ
drugs_NN
,_,
46_CD
many_QUAN
major_JJ
diseases_NN
and_PHC
illnesses_NOMZ
._.
development_NOMZ
,_,
572016_CD
,_,
is_VPRT [BEMA]
hopefully_RB
one_CD
inflammation_NOMZ
in_PIN
arterial_JJ
walls_NN
._.
modern_JJ
day_NN
research_NN
will_PRMD
provide_VB
per_PIN
cent_NN
of_PIN
breast_NN
cancer_NN
patients_NN
such_JJ
treatment_NOMZ
._.
So_RB
far_PLACE
the_DT
results_NN
are_VPRT
hope_NN
for_PIN
sufferers_NN
._.
treated_VBN [PASTP]
with_PIN
572016_CD
showed_VBD [PRIV]
either_CC
extremely_AMP
encouraging_JJ
._.
We_FPP1
have_VPRT
huge_JJ
a_DT
partial_JJ
response_NN
or_CC
stable_JJ
disease_NN
._.
hopes_NN
for_PIN
it_PIT
and_CC
maybe_HDG
the_DT
future_NN
will_PRMD
One_CD
of_PIN
the_DT
compounds_NN
featured_VBD
see_VB [PRIV]
an_DT
even_RB
better_JJ
572016_CD
._.
on_PIN
this_DEMO
page_NN
is_VPRT [BEMA]
a_DT
first_JJ
of_PIN
its_PIT
kind_NN
._.
Each_QUAN
On_PIN
a_DT
December_NN
day_NN
in_PIN
1998_CD
,_,
the_DT
full_JJ
The_DT
investigational_JJ
compound_NN
,_,
and_ANDC
every_QUAN
day_NN
,_,
GSK_NN
spends_VPRT
nearly_DWNT
572016_CD
,_,
is_VPRT [BEMA]
a_DT
dual_JJ
kinase_NN
inhibitor_NN
8_CD
million_CD
in_PIN
research_NN
for_PIN
future_JJ
number_NN
of_PIN
this_DEMO
compound_NN
was_VBD [PASS]
scrawled_VBN
being_VBG [PASS]
studied_VBN
for_PIN
the_DT
treatment_NOMZ
of_PIN
therapies_NN
therapies_NN
that_TSUB
will_PRMD
on_PIN
a_DT
whiteboard_NN
in_PIN
Tonas_NN
office_NN
by_PIN
a_DT
solid_JJ
tumors_NN
._.
provide_VB
hope_NN
for_PIN
millions_NN
of_PIN
people_NN
._.
This_DEMP
is_VPRT [BEMA]
it_PIT
-_:
this_DEMP
is_VPRT [BEMA]
the_DT
one_CD
,_,
he_TPP3
said_VBD [PUBV]
._.
It_PIT
is_VPRT [BEMA]
a_DT
daily_JJ
oral_JJ
therapy_NN
under_IN
Im_NN
never_RB
going_VBG
to_TO
remove_VB
it_PIT
,_,
said_VBD [PUBV]
investigation_NOMZ
for_PIN
advanced_JJ
breast_NN
Tona_NN
._.
moment_NOMZ
and_PHC
cancer_NN
,_,
non-small_JJ
cell_NN
lung_NN
,_,
bladder_NN
,_,
part_NN
of_PIN
the_DT
excitement_NOMZ
of_PIN
our_FPP1
work_NN
,_,
all_QUAN
of_PIN
gastric_JJ
and_CC
head_NN
and_PHC
neck_NN
cancers_NN
._.
which_WDT [SERE]
is_VPRT [BEMA]
such_EMPH
a_NULL
great_JJ
opportunity_NOMZ
to_TO
help_VB
It_PIT
blocks_VPRT
two_CD
of_PIN
the_DT
kinases_NN
answer_VB
the_DT
sort_NN
of_PIN
questions_NOMZ
I_FPP1
have_VPRT [PEAS]
had_VBN
for_PIN
so_EMPH
long_JJ
._.
